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Abstract
Background: Carcinomas of the renal pelvis and ureter are rare diseases, accounting for only about 1% of all urogenital   malignancies. 
Previous reports suggest that squamous cell histology is associated with inferior survival. We present the largest population based analy-
sis to date of survival in patients with upper urinary tract malignancies. 
Methods: We analyzed the Surveillance, Epidemiology and End Results database for cancer specific survival rates in patients with renal 
pelvis and ureteral malignancies who were diagnosed between 1973 and 2003 in the SEER catchment geographic areas. The primary 
exposure of interest was the underlying histology, squamous cell versus transitional cell differentiation. We performed descriptive 
  statistics, non parametric survival analysis, and cox proportional hazard analysis. 
Results: We identified 13,213 eligible patients, 7,716 renal pelvis and 5,497 ureteral carcinomas. Among this cohort, 179 patients had 
squamous cell carcinoma (SCC), 12,395 had transitional cell carcinoma (TCC), including 121 papillary, and 619 had other histologies. 
Overall, patients with SCC histology fared worse. The median overall survival time was 10 months for SCC and 63 months for TCC. 
The cox analysis revealed a HR 3.7 (95% CI 3.0–4.5) for SCC when compared to TCC and corrected for decade of diagnosis, age, 
gender, prior treatment, and race. The difference between the two groups was entirely attributable to survival differences in patients 
with loco-regional disease. However, when stratified by lymph node involvement this difference disappeared for patients with locally 
involved lymph nodes (P = 0.84) and for patients with clear lymph nodes (P = 0.92). 
Conclusions: SCCs of the upper urinary tract present at a higher clinical stage and appear to represent more aggressive disease when 
compared to other histologies. However, when appropriately staged according to lymph node status, the survival of TCC and SCC of 
the upper urinary tract is identical when compared stage by stage.
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Introduction
Neoplasms of the upper urogenital tracts involving 
the renal pelvis and ureter are defined as any neoplas-
tic growth involving the lining of the urinary tract 
from the renal calyces to the ureterovesical junction.1 
These tumors are rare representing less than one per-
cent of genitourinary malignancies.2,3 The incidence 
of neoplasms of the upper urinary tract in the United 
States has increased slightly over the last 20 years 
from an annual incidence of 0.69 to 0.73/1000,000 
person years from 1973 to 1996.4 The paucity of cases 
makes it difficult to establish a standard of care for 
these malignancies and the prognosis remains poor. 
Squamous cell histology represents only a small frac-
tion of the total number of malignancies of the upper 
urinary tract (UUT). Most of our knowledge about 
these  rare  malignancies  originates  from  anecdotal 
evidence and squamous cell histology, in particular, 
has been associated with a poor prognosis.5–10 A recent 
retrospective registry study from Sweden challenged 
this assumption.11 We present the largest registry of 
UUT malignancies to date and investigate the impact 
of squamous cell histology on overall survival and 
cancer specific survival.
patient and Methods
The database
For  our  cohort  we  utilized  publicly  available  data 
from  the  National  Cancer  Institute  Surveillance, 
  Epidemiology,  and  End  Results  (SEER)  database 
from 1973 to 2004. The SEER program is an effort by 
the United States (US) government to collect data and 
report cancer incidence, treatment, and survival. The 
database represents about 10 percent of the US popu-
lation by collecting information from 14 population 
based cancer registries around the country. Trained 
abstractors collect data on patient age, sex, site, histo-
logical findings, tumor grade, and stage from hospital 
records, outpatient clinics, radiation centers, private 
laboratories and physician offices. For coding pur-
poses the ICD-O-3 classification was used.12
Patients
Patients were eligible if they presented between 1973 
and 2004 with a malignancy of the renal pelvis or 
  ureter (site coding C65.9 and C66.9). To allow for 
sufficient maturation, only patients presenting until 
the end of 2003 were included in the survival analysis. 
Only  patients  with  a  clearly  malignant  coded 
  phenotype were included. The primary exposure of 
interest  was  the  underlying  histology.  Histologies 
were subdivided into squamous cell (SC), transitional 
cell (TC), (including the papillary subtype) and other 
histologies  (OT)  (mainly  small  cell,  sarcomatoid 
and undifferentiated carcinomas). The primary out-
come of interest was cancer specific survival. We also 
examined overall survival and performed sensitivity 
analyses, excluding and right censoring patients who 
died from causes other than UUT malignancies. Since 
survival  prognosticators  in  UUT  malignancies  are 
poorly delineated, we examined race, prior surgery 
and radiotherapy, decade of diagnosis, age at diag-
nosis, gender, preceding malignancies and stage as 
potential predictors of the primary outcome and can-
cer specific survival. Race was coded as Caucasian, 
Black, Hispanic or Asian/other. The other category 
included  mainly  smaller Asian  subpopulations  and 
the indigenous population of the Western hemisphere. 
Decade of diagnosis was coded into the 70s, 80s, 90s 
and 2000s, while the age group was subdivided into 
49 or younger, 50 to 75, and older than 75 years of age 
at diagnosis. Prior therapies were classified as having 
been received or not. Secondary to coding issues, we 
utilized the traditional American Joint   Committee on 
Cancer (AJCC) staging classification, which entails 
the following stages: in situ, local, regional and   distant. 
The regional stage included patients with extension 
beyond the ureter or renal pelvis and patients with 
documented lymph node involvement.
Statistical methods
We examined descriptive statistics to describe demo-
graphic  composition  of  the  study  population  and 
distribution  of  the  other  relevant  predictors  of  the 
outcome. Uni-variate Kaplan Meier survival analysis 
was performed to investigate which variables were of 
predictive relevance. In our cancer specific survival 
analysis, the patients who died from a cause other 
than a malignancy of the upper urinary tract were 
right censored.
We examined race, prior surgery and   radiotherapy, 
decade  of  diagnosis,  age  at  diagnosis,  gender, 
  preceding malignancies and stage as other potential 
predictors of outcome and retained them in our final 
Cox  proportional  hazard  (Cox  PH)  model  if  they 
had a significant impact on survival on   univariate, 
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non parametric analysis. Differences along the strata 
of predictors of interest were evaluated using a log 
rank test. If the log rank test was statistically signifi-
cant, the covariates were retained in the final model. 
In the final model, we performed Cox proportional 
hazards  regression  to  determine  hazard  ratios.13 
  Post-estimation diagnostics were performed to ana-
lyze if the proportional hazard assumptions were vio-
lated, using graphical and computational methods.14,15 
All  analyses  were  performed  using  STATA  9.0 
  (College Station, TX).
Results
We identified 13,213 patients with malignancies of 
the UUT. One hundred and ninety nine patients had 
squamous cell malignancies of the UUT and 12,395 
had transitional or papillary histology. Overall most 
patients were of Caucasian origin, although relatively 
more patients with squamous cell carcinomas were 
of Asian ethnicity. Most patients underwent surgery 
and only a small fraction of patients obtained radia-
tion as part of their treatment. Interesting is that only 
a  small  fraction  of  patients  with  locoregional  dis-
ease obtained appropriate lymph node sampling and 
recording. Most patients with loco-regional disease 
had an unknown loco-regional lymph nodes status. 
Eighty  eight  (88.0%)  patients  with  squamous  cell 
  histology and 3,624 (84.8%) with transitional cell his-
tology and loco-regional disease had no appropriate 
recording of their loco-regional lymph node status. 
Baseline characteristics by histology are displayed in 
Table 1. Transitional carcinomas and other histolo-
gies demonstrated male gender predominance, while 
the gender distribution for squamous cell carcinomas 
was equally balanced. Appropriate lymph node sam-
pling  in  surgically  resected  cases  was  consistently 
reported in less than twenty percent, an observation 
that has persisted into the 21st century. Patients with 
squamous cell malignancies were more likely to pres-
ent with regional (P , 0.01) and distant (P , 0.01) 
disease, while TCC had a higher likelihood to pres-
ent at a local (P , 0.01) or in situ stage (P , 0.01). 
Patients with squamous cell histology were less likely 
to undergo radiation therapy (P , 0.01) and surgery 
(P , 0.01).
At  the  time  of  our  analysis  approximately 
56%  of  patients  with  squamous  cell  malignancies 
of  the  upper  urothelial  tract  had  died  from  their 
underlying malignancies. The death rate from   bladder 
tumors was consistently less than or equal to 1% (2 in 
the squamous cell group and 93 in the TCC group). 
The overall survival for patients who   presented with 
UUT squamous cell cancer was significantly worse 
than for TCC (see Kaplan Meier graph A in graph 1). 
We retained race, prior surgery and/or   radiotherapy, 
decade  of  diagnosis,  age  at  diagnosis,  gender  and 
stage in our final model. Of note is that the   covariate 
stage was introduced as described above, utilizing the 
above described staging classification, which   collapses 
extension beyond the organ (renal   pelvis or ureter) and 
local lymph node involvement into regional   disease. 
We  performed  Cox  proportional  hazard    modeling 
for cancer specific survival, adjusting for race, prior 
surgery and radiotherapy, decade of diagnosis, age 
at  diagnosis,  gender,    preceding    malignancies  and 
stage.  We  then  examined  the  survival  difference 
for regional and metastatic disease across the three 
different    histologies.  As  graphically  illustrated  in 
Kaplan Meier graph C, no significant difference in 
survival was established for patients presenting with 
metastatic disease. The major difference in survival 
is most notable in the patient group presenting with 
regional stage disease (graph B).
As outlined in Table 1 of the 4,499 patients with 
regional disease only 684 patients obtained appropri-
ate lymph node sampling (12 with squamous, 648 
with transitional cell and 24 with other histological 
subtype). Graphs D and E of panel 1 demonstrate the 
survival of patients with loco-regional disease and 
known lymph node status for TCC (graph D) and 
SCC(graph  E),  respectively.  In  the  group  of  TCC 
patients with regional and reported lymph node sta-
tus, survival was significantly decreased in patients 
with positive lymph nodes (P , 0.01) (graph D). In 
the small group of patients with SCC no survival dif-
ference could be observed in the patients with posi-
tive or absent lymph node involvement (P = 0.63) 
(graph F).
Table 2 outlines the fraction of patients with the dif-
ferent histologies still alive at 6, 12, 24 and 60 months 
after diagnosis. A graphical depiction of these patients’ 
overall survival estimate is shown in graph A of panel 1. 
In the upper part of the table we also demonstrate the 
semi-parametrical survival estimates, displaying haz-
ard ratios, using patients with transitional cell carcino-
mas as reference group. It clearly illustrates the inferior 
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Table 1.
squamous histology Transitional and  
papillary histology
Other histologies
Renal pelvis Ureter Both sites Renal pelvis Ureter Both sites Renal pelvis Ureter Both sites
gender
  Men 
  Women
56 (46.3%) 
65 (53.7%)
42 (53.9%) 
36 (46.1%)
98 (49.3%) 
101 (50.7%)
4396 (60.4%) 
2883 (39.6%)
3377 (66.0%) 
1739 (34.0%)
7,773 (62.7%) 
4,622 (37.3%)
190 (60.1%) 
126 (39.9%)
192 (63.3%) 
111 (36.6%)
382 (61.7%) 
237 (38.3%)
race
  Caucasian 
  Blacks 
  hispanics 
  Asian/other
102 (84.3%) 
7 (5.8%) 
3 (2.5%) 
9 (7.4%)
62 (79.5%) 
5 (6.4%) 
4 (5.1%) 
7 (8.9%)
164 (82.4%) 
12 (6.0%) 
7 (3.5%) 
16 (8.1%)
6376 (87.6%) 
308 (4.2%) 
200 (2.8%) 
395 (5.4%)
4574 (89.4%) 
131 (2.6%) 
117 (2.3%) 
294 (5.8%)
10,950 (88.3%) 
439 (3.5%) 
317 (2.6%) 
689 (5.6%)
260 (82.3) 
24 (7.6%) 
16 (5.0%) 
16 (5.0%)
264 (87.1%) 
19 (6.3%) 
5 (1.7%) 
15 (5.0%)
524 (84.6%) 
43 (7.0%) 
21 (3.4%) 
31 (5.0%)
Age group
  30–49 years old 
  50–74 years old 
  .75 years old
11 (9.1%) 
60 (49.6%) 
50 (41.3%)
4 (5.1%) 
51 (65.4%) 
23 (29.5%)
15 (7.5%) 
111 (55.8%) 
73 (36.7%)
438 (6.0%) 
4199 (57.7%) 
2642 (36.3%)
166 (3.2%) 
2945 (57.6) 
2005 (39.2%)
604 (4.9%) 
7,144 (57.6%) 
4,647 (37.5%)
42 (13.3%) 
174 (55.0%) 
100 (31.7%)
17 (5.6%) 
155 (51.2%) 
131 (43.23%)
59 (9.5%) 
329 (53.2%) 
231 (37.3%)
Decade of diagnosis
  1973–1979 
  1980–1989 
  1990–1999 
  2000–2004
35 (28.9%) 
39 (32.2%) 
34 (28.1%) 
13 (10.7%)
16 (20.5%) 
30 (38.5%) 
21 (26.9%) 
11 (14.1%)
51 (25.6%) 
69 (34.7%) 
55 (27.6%) 
24 (12.1%)
1251 (17.2%) 
2142 (29.4%) 
2524 (34.7%) 
1362 (18.7%)
751 (14.7%) 
1486 (29.0%) 
1836 (35.9%) 
1043 (20.4%)
2,002 (16.2%) 
3,628 (29.3%) 
4,360 (35.2%) 
2,405 (19.4%)
82 (25.9%) 
92 (29.1%) 
96 (30.4%) 
46 (14.6%)
53 (17.5%) 
103 (34.0%) 
95 (31.4%) 
52 (177.2%)
135 (21.8%) 
195 (31.5%) 
191 (30.9%) 
98 (15.8%)
Stage
  In situ 
  Local 
  regional 
    *-Ln+ 
    *-Ln- 
    *-not available 
  Distal 
  Insuff. Inform.
1 (0.8%) 
14 (11.6%) 
56 (46.3%) 
5 (8.9%) 
4 (7.1%) 
47 (83.9%) 
40 (33.1%) 
10 (8.3%)
3 (3.9%) 
15 (19.2%) 
44 (56.4%) 
2 (4.5%) 
1 (2.3%) 
(93.2%) 
13 (16.7%) 
3 (3.9%)
4 (2.0%) 
29 (14.6%) 
100 (50.3%) 
7 (7.0%) 
5 (5.0%) 
88 (88.0%) 
53 (26.6%) 
13 (6.5%)
1158 (15.9%) 
2502 (34.4%) 
2666 (36.6%) 
195 (7.3%) 
222 (8.3%) 
2,249 (84.4%) 
650 (8.9%) 
303 (4.2%)
1261 (24.7%) 
1757 (34.3%) 
1606 (31.4%) 
89 (5.5%) 
142 (8.8%) 
1,375 (85.6%) 
260 (5.0%) 
232 (4.5%)
2,419 (19.5%) 
4,259 (34.4%) 
4,272 (34.5%) 
284 (6.7%) 
364 (8.5%) 
3,624 (84.8%) 
910 (7.3%) 
535 (4.3%)
16 (5.0%) 
85 (26.9%) 
78 (24.7%) 
10 (12.8%) 
9 (11.5%) 
59 (75.6%) 
82 (26.0%) 
55 (17.4%)
102 (33.7%) 
39 (12.9%) 
49 (16.2%) 
3 (6.1%) 
2 (4.1%) 
44 (89.8% 
37 (12.2%) 
76 (25.1%)
118 (19.1%) 
124 (20.0%) 
127 (20.5%) 
13 (10.2%) 
11 (8.7%) 
103 (81.1%) 
119 (19.2%) 
131 (21.2%)
Surgery
  Yes 
  no
94 (77.7%) 
27 (22.3%)
62 (79.5%) 
16 (20.5%)
156 (78.4%) 
43 (21.6%)
6561 (90.1%) 
718 (9.9%)
4622 (90.3%) 
494 (9.7%)
11,183 (90.2%) 
1,212 (9.8%)
188 (59.5%) 
128 (40.5%)
181 (59.7%) 
122 (40.3%)
369 (59.6%) 
250 (40.4%)
radiation
  Yes 
  no
19 (15.70%) 
102 (84.30%)
24 (30.77%) 
54 (69.23%)
43 (21.6%) 
156 (78.4%)
425 (5.8%) 
6854 (94.2%)
357 (7.0%) 
4759 (93.0%)
782 (6.3%) 
11,613 (93.7%)
39 (12.3%) 
277 (87.7%)
33 (10.9%) 
270 (89.1%)
72 (11.6%) 
547 (88.4%)
notes: *The percentage figure refers to the total amount of cases in the regional disease category. The table above displays the distribution of clinically 
relevant disease characteristics for patients with UUT malignancies across the different histologies, ie, transitional cell, squamous cell and others (mainly 
small cell, sarcomatoid and undifferentiated carcinomas).
survival of patients with squamous cell carcinomas, 
when all presenting patients (all stages) are compared 
to  patients  to  patients  with TCC. Although  a  trend 
towards an improved survival is identified in patients 
with papillary subhistology, when compared with TCC 
patients, this did not reach statistical significance.
Discussion
We  present  the  largest  registry  based  study  of 
squamous cell malignancies of the upper urothelial 
tract to date. The fraction of SCC in malignancies of 
the upper urinary tract was 1.5% in our cohort. This is 
in the range of previous publications which reported 
the incidence to be 0.7% to 10%.1,8,9,11,16
Most previously published reports regarding the 
outcome of patients with SCC of the UUT are case 
reports or small series.6–9 The largest study published 
to date is a retrospective, registry based study from 
Sweden.11 The strength of this Swedish study, which 
included 743 patients with transitional cell and 65 
with squamous cell histology, was a central review 
process  of  the  majority  of  the  specimens  and  the 
availability of clinical details from review of   hospital 
records.
Our  study  reveals  several  interesting  findings. 
First, SCC of the UUT present on average with more 
advanced stages when compared to TCCs. This can 
probably be explained by a more aggressive biology 
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Table 1.
squamous histology Transitional and  
papillary histology
Other histologies
Renal pelvis Ureter Both sites Renal pelvis Ureter Both sites Renal pelvis Ureter Both sites
gender
  Men 
  Women
56 (46.3%) 
65 (53.7%)
42 (53.9%) 
36 (46.1%)
98 (49.3%) 
101 (50.7%)
4396 (60.4%) 
2883 (39.6%)
3377 (66.0%) 
1739 (34.0%)
7,773 (62.7%) 
4,622 (37.3%)
190 (60.1%) 
126 (39.9%)
192 (63.3%) 
111 (36.6%)
382 (61.7%) 
237 (38.3%)
race
  Caucasian 
  Blacks 
  hispanics 
  Asian/other
102 (84.3%) 
7 (5.8%) 
3 (2.5%) 
9 (7.4%)
62 (79.5%) 
5 (6.4%) 
4 (5.1%) 
7 (8.9%)
164 (82.4%) 
12 (6.0%) 
7 (3.5%) 
16 (8.1%)
6376 (87.6%) 
308 (4.2%) 
200 (2.8%) 
395 (5.4%)
4574 (89.4%) 
131 (2.6%) 
117 (2.3%) 
294 (5.8%)
10,950 (88.3%) 
439 (3.5%) 
317 (2.6%) 
689 (5.6%)
260 (82.3) 
24 (7.6%) 
16 (5.0%) 
16 (5.0%)
264 (87.1%) 
19 (6.3%) 
5 (1.7%) 
15 (5.0%)
524 (84.6%) 
43 (7.0%) 
21 (3.4%) 
31 (5.0%)
Age group
  30–49 years old 
  50–74 years old 
  .75 years old
11 (9.1%) 
60 (49.6%) 
50 (41.3%)
4 (5.1%) 
51 (65.4%) 
23 (29.5%)
15 (7.5%) 
111 (55.8%) 
73 (36.7%)
438 (6.0%) 
4199 (57.7%) 
2642 (36.3%)
166 (3.2%) 
2945 (57.6) 
2005 (39.2%)
604 (4.9%) 
7,144 (57.6%) 
4,647 (37.5%)
42 (13.3%) 
174 (55.0%) 
100 (31.7%)
17 (5.6%) 
155 (51.2%) 
131 (43.23%)
59 (9.5%) 
329 (53.2%) 
231 (37.3%)
Decade of diagnosis
  1973–1979 
  1980–1989 
  1990–1999 
  2000–2004
35 (28.9%) 
39 (32.2%) 
34 (28.1%) 
13 (10.7%)
16 (20.5%) 
30 (38.5%) 
21 (26.9%) 
11 (14.1%)
51 (25.6%) 
69 (34.7%) 
55 (27.6%) 
24 (12.1%)
1251 (17.2%) 
2142 (29.4%) 
2524 (34.7%) 
1362 (18.7%)
751 (14.7%) 
1486 (29.0%) 
1836 (35.9%) 
1043 (20.4%)
2,002 (16.2%) 
3,628 (29.3%) 
4,360 (35.2%) 
2,405 (19.4%)
82 (25.9%) 
92 (29.1%) 
96 (30.4%) 
46 (14.6%)
53 (17.5%) 
103 (34.0%) 
95 (31.4%) 
52 (177.2%)
135 (21.8%) 
195 (31.5%) 
191 (30.9%) 
98 (15.8%)
Stage
  In situ 
  Local 
  regional 
    *-Ln+ 
    *-Ln- 
    *-not available 
  Distal 
  Insuff. Inform.
1 (0.8%) 
14 (11.6%) 
56 (46.3%) 
5 (8.9%) 
4 (7.1%) 
47 (83.9%) 
40 (33.1%) 
10 (8.3%)
3 (3.9%) 
15 (19.2%) 
44 (56.4%) 
2 (4.5%) 
1 (2.3%) 
(93.2%) 
13 (16.7%) 
3 (3.9%)
4 (2.0%) 
29 (14.6%) 
100 (50.3%) 
7 (7.0%) 
5 (5.0%) 
88 (88.0%) 
53 (26.6%) 
13 (6.5%)
1158 (15.9%) 
2502 (34.4%) 
2666 (36.6%) 
195 (7.3%) 
222 (8.3%) 
2,249 (84.4%) 
650 (8.9%) 
303 (4.2%)
1261 (24.7%) 
1757 (34.3%) 
1606 (31.4%) 
89 (5.5%) 
142 (8.8%) 
1,375 (85.6%) 
260 (5.0%) 
232 (4.5%)
2,419 (19.5%) 
4,259 (34.4%) 
4,272 (34.5%) 
284 (6.7%) 
364 (8.5%) 
3,624 (84.8%) 
910 (7.3%) 
535 (4.3%)
16 (5.0%) 
85 (26.9%) 
78 (24.7%) 
10 (12.8%) 
9 (11.5%) 
59 (75.6%) 
82 (26.0%) 
55 (17.4%)
102 (33.7%) 
39 (12.9%) 
49 (16.2%) 
3 (6.1%) 
2 (4.1%) 
44 (89.8% 
37 (12.2%) 
76 (25.1%)
118 (19.1%) 
124 (20.0%) 
127 (20.5%) 
13 (10.2%) 
11 (8.7%) 
103 (81.1%) 
119 (19.2%) 
131 (21.2%)
Surgery
  Yes 
  no
94 (77.7%) 
27 (22.3%)
62 (79.5%) 
16 (20.5%)
156 (78.4%) 
43 (21.6%)
6561 (90.1%) 
718 (9.9%)
4622 (90.3%) 
494 (9.7%)
11,183 (90.2%) 
1,212 (9.8%)
188 (59.5%) 
128 (40.5%)
181 (59.7%) 
122 (40.3%)
369 (59.6%) 
250 (40.4%)
radiation
  Yes 
  no
19 (15.70%) 
102 (84.30%)
24 (30.77%) 
54 (69.23%)
43 (21.6%) 
156 (78.4%)
425 (5.8%) 
6854 (94.2%)
357 (7.0%) 
4759 (93.0%)
782 (6.3%) 
11,613 (93.7%)
39 (12.3%) 
277 (87.7%)
33 (10.9%) 
270 (89.1%)
72 (11.6%) 
547 (88.4%)
notes: *The percentage figure refers to the total amount of cases in the regional disease category. The table above displays the distribution of clinically 
relevant disease characteristics for patients with UUT malignancies across the different histologies, ie, transitional cell, squamous cell and others (mainly 
small cell, sarcomatoid and undifferentiated carcinomas).
and a lower incidence of clinical warning signs, such 
as hematuria, in patients with SCC. Second, the over-
all survival for patients diagnosed in the US with SCC 
of the UUT is dismal and overall inferior to patients 
with TCC. Third, stage for stage the survival differ-
ence between squamous and transitional histologies 
is less pronounced. This is in accordance to the prior 
Swedish study by Holmang et al,3 which demonstrated 
an equally poor prognosis for both tumor types when 
only advanced stages were considered. Holmang et al 
observed a trend towards a decreased survival in SCC 
that did not reach statistical significance (P = 0.099) 
in  patients  with  pT3.11  In  our  study  the  survival 
difference at six and twelve months after diagnosis 
did reach statistical   significance. This is largely due to 
the greater number of observed events thus resulting 
in a higher statistical power in our study. Fourth, our 
study demonstrates that patients with TCC involving 
the  regional  lymph  nodes  fare  significantly  worse 
than  patients  with  disease  extending  beyond  the 
organ. This is reflected in the current TNM staging 
classification17 which considers regional lymph node 
involvement as stage IV disease. Interestingly, this 
survival difference is less pronounced in patients with 
SCC and regional disease. Unfortunately, the paucity 
of  data  on  patients  in  our  registry  with  SCC  and 
regional disease of the UUT and inadequate lymph 
node sampling does not allow for a firm conclusion 
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panel 1. The panel above graphically illustrates the survival of patients with UUT malignancies. graph A demonstrates the survival by histology. All stages 
are considered. Graph B considers only the patients presenting with regional disease, ie, patients with malignancies beyond the confinement of the renal 
pelvis or ureter or positive lymph node involvement. graph C displays the survival of patients with metastatic disease, by histology. graph D illustrates the 
survival of patients with locoregional disease and known lymph node status. All histologies are included. graph e demonstrates the superior survival of 
patients with absent lymph node involvement in patients with transitional cell histology and regional disease status. graph F demonstrates the absence of 
a significant difference by lymph node status in patients with regional disease status and squamous cell histology.
regarding  the    prognostic  relevance  of  local  lymph 
node status in patients with SCC of the UUT. Lastly, 
we  did  not  observe  a  high  association  between 
malignancies  of  the  UUT  and  death  from  bladder 
cancer. Patients in our study only rarely died from 
bladder cancer (#1%). This is in contrast to previous 
reports.18 However, we recognize the high percentage 
of patients with UUT malignancy that will develop 
lower  urinary  tract  tumors  and  the  importance  of 
regular lower urinary tract surveillance.
16  Clinical Medicine Insights: Oncology 2012:6Squamous cell carcinoma of the upper urinary tract
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Our study has several shortcomings. First, the SEER 
registry obtains information from medical charts and, 
therefore, the registry data can only be as accurate as 
the medical record from which it is obtained. Second, 
clinical history and comorbidities cannot be obtained 
from the SEER registry. This might have introduced 
a  bias  of  differential  attrition  across  the  different 
  histological subtypes into our study. Third, although 
the SEER registry provides information about post-
  operative radiotherapy, this has never been shown to 
be of benefit to patient survival in UUT.19,20 At least 
three retrospective studies have suggested some ben-
efit from adjuvant chemotherapy.21–23 Unfortunately, 
the  SEER  database  does  not  provide  data  about 
administered chemotherapy. Lastly, the stage coding 
on patients with UUT malignancies was largely done 
in the old AJCC Staging system. This classification 
collapses local lymph node involvement and tumors 
exceeding the confinement of the involved organ into 
the regional stage category. As demonstrated above 
this leads to inaccurate prognostication, at least in 
TCCs. Hence, our reported hazard ratio has to be con-
sidered with caution.
Despites the shortcomings, the size of this study 
and the quality of the performed statistical analysis 
does provide a valuable addition to the existing, but 
limited, body of literature on squamous cell malig-
nancies of the UUT.
conclusion
Squamous cell cancers of the upper urinary tract are 
associated with a poor prognosis. Overall, patients 
with SCC present with more advanced disease and 
have lower survival rates when compared to their tran-
sitional cell counterparts. Lymph node dissection has 
not been a standard part of the surgical management 
of UUT. However, the lymph node status in patients 
with UUT provides further information to help give 
patients more accurate prognoses. To improve this 
prognosis the rigorous future study of effective sys-
temic chemotherapy for palliative and adjuvant treat-
ment, especially in patients with advanced disease, is 
needed.
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